(Total Views: 464)
Posted On: 04/20/2020 3:22:58 PM
Post# of 72446
Really enjoyed this part. IMO is only a matter of time before you see our drug on TV and used in patients. We know it’s safe already.
Brilacidin could be developed, most immediately based on existing safety and efficacy data, as an intravenous drug (direct treatment), whether administered as a monotherapy or in combination, potentially leveraging synergies with other drugs or antivirals, as is being done (e.g., Hydroxychloroquine and azithromycin; antivirals and anti-inflammatories6, e.g., remdesivir and sarilumab).
Importantly, Brilacidin is one of the few drugs currently in clinical development and among drugs already approved that has shown direct antiviral properties against SARS-CoV-2, the novel coronavirus responsible for COVID-19, in a cell- based assay, with additional research planned by academic collaborators.
Drugs that are even modestly active7 against the novel coronavirus, particularly ones with safe therapeutic profiles having been evaluated earlier in rigorous placebo-controlled clinical trials, might not only save the lives of severely ill patients, but might also be given prophylactically to protect
health care workers and others at risk of infection. Such treatments may also reduce the time patients spend in ICUs, freeing up hospital beds.
Brilacidin could be developed, most immediately based on existing safety and efficacy data, as an intravenous drug (direct treatment), whether administered as a monotherapy or in combination, potentially leveraging synergies with other drugs or antivirals, as is being done (e.g., Hydroxychloroquine and azithromycin; antivirals and anti-inflammatories6, e.g., remdesivir and sarilumab).
Importantly, Brilacidin is one of the few drugs currently in clinical development and among drugs already approved that has shown direct antiviral properties against SARS-CoV-2, the novel coronavirus responsible for COVID-19, in a cell- based assay, with additional research planned by academic collaborators.
Drugs that are even modestly active7 against the novel coronavirus, particularly ones with safe therapeutic profiles having been evaluated earlier in rigorous placebo-controlled clinical trials, might not only save the lives of severely ill patients, but might also be given prophylactically to protect
health care workers and others at risk of infection. Such treatments may also reduce the time patients spend in ICUs, freeing up hospital beds.
(3)
(0)
